Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633708 | 1.00 | PIK3C3 (0.72) | PIK3C3 | |
| SCHEMBL22654565 | 1.00 | PIK3C3 (0.72) | PIK3C3 | |
| SCHEMBL22654569 | 0.90 | PIK3C3 (0.69) | PIK3C3 | |
| SCHEMBL29633644 | 0.90 | PIK3C3 (0.69) | PIK3C3 | |
| SCHEMBL30288864 | 0.90 | PIK3C3 (0.69) | PIK3C3 | |
| SCHEMBL22654572 | 0.90 | PIK3C3 (0.69) | PIK3C3 | |
| SCHEMBL20777027 | 0.90 | PIK3C3 (0.69) | PIK3C3 | |
| SCHEMBL24470269 | 0.84 | PIK3C3 (1.00) | PIK3C3 | |
| SCHEMBL19272649 | 0.84 | PIK3C3 (1.00) | PIK3C3 | |
| SCHEMBL19259530 | 0.84 | PIK3C3 (1.00) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | claimed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | claimed |
| WO-2023019259-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-16 | — | — | WO | claimed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| CN-116462674-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116444510-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-111108102-B | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-4056569-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2022-09-14 | — | — | EP | disclosed |
| EP-3672962-B1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2022-01-26 | — | — | EP | disclosed |
| EP-3672962-B1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2022-01-26 | — | — | EP | disclosed |
| US-20200361922-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2020-11-19 | — | — | US | disclosed |
| US-20200361922-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2020-11-19 | — | — | US | disclosed |
| EP-3672962-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| CN-111108102-A | Morpholinopyridone compounds | 思普瑞特生物科学公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019038390-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038390-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361922-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | MAP1B, RRP12, MYT1 | PIK3C3 3743/4885 |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | MAP1B, RRP12, MYT1 | PIK3C3 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.